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INTRODUCTION 
 
Animal venoms are rich sources of natural lead 
molecules with therapeutic potential. However, 
their structural and/or functional properties often 
have to be improved to get candidate drugs. 
Strategies to obtain such optimized molecules 
are reviewed herein. 
 
PEPTIDE SYNTHESIS VS GENETIC 
ENGINEERING 
 
In animal venoms, peptide sizes are mainly in the 
range of 0.4 to 8.0 kDa. This would correspond to 
peptides of ca. 4 to 70 amino acid residues, with 
a number of potential therapeutic applications.
[1]
 
Because of the intrinsic structural complexities of 
these peptides (different types of fold and 1-5 
disulfide bridges), this size range implicates that 
only a fraction of them (< 50-mer peptides) can 
routinely be produced by chemical synthesis.
[2,3]
  
Longer peptides are more difficult to produce 
chemically and have generally required the use 
of molecular biology techniques for their 
productions. Basically, chemical synthesis has 
several advantages over genetic engineering 
making the former approach more appropriate to 
improve the structural and functional properties of 
peptides of interest. In particular, the possibility to 
incorporate non-natural amino acid derivatives or 
ABSTRACT 
Background: venoms of a variety of animal species (i.e. scorpions, snakes, 
spiders, sea anemones, marine cone snails, worms, and insects) are rich sources 
of bioactive compounds that possess obvious pharmacological, therapeutic 
and/or biotechnological values. A majority of these compounds are peptides that 
mainly target enzymes, membrane receptors or ion channels. Aim: In recent 
years, much efforts of researchers have been focused on characterizing and 
‘improving’ the pharmacological profile of some venom toxins, mainly because of 
their structural/functional diversity and potential value as chemotherapeutic drugs 
in the treatment of specific human pathologies. Materials and methods: This 
study reviews the strategies towards optimization of animal peptide toxins. 
Results: These peptides are most often in a size range that allows their 
production in vitro by chemical synthesis or genetic engineering. Unfortunately, 
they rarely display the required characteristics in terms of selectivity, affinity, 
stability and targeting with regard to the desired application. During the last 
decade, a number of successful structural approaches or strategies have been 
developed to improve the intrinsic potential of venom peptides. Using different 
strategies (reviewed herein), a number of highly potent and selective toxin-
derived candidate drugs were designed and produced by chemical synthesis. 
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are already marketed while an increasing number of candidate 
chemotherapeutics are currently being developed in clinical phase. 
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to form non-amide pseudo-peptide bonds is a 
definite benefit over genetic production. Also, the 
high yields of peptide productions are assets for 
detailed structural analyses and functional 
characterizations of the peptides. Finally, the 
production of peptides for therapeutic purposes is 
less cumbersome when a chemical approach is 
chosen over a genetic one. Indeed, safety, 
reproducibility and lack of cell contaminants 
clearly argue in favor of chemical synthesis. In 
fact, the vast majority of studies relating 
structure-function analyses are based on 
peptides produced by chemical synthesis. 
 
PEPTIDE OPTIMIZATION NEEDS 
SIGNIFICANT BASIC KNOWLEDGE 
ON ‘LEAD’ PROPERTIES 
 
For valuable strategies of peptide improvement, 
one needs to know the peptide target(s), 3-D 
structure, functional effect(s) and specific 
application(s) pursued. With uncharacterized 
venom peptides, identification of actual target(s) 
is generally a difficult task. Pharmacological 
profiling using well defined screening approaches 
often reveals that peptides recognize several 
targets (e.g. different ion channel types) or may 
be derived for multiple applications. From 
pharmacological studies, some precious 
information can be gained that include peptide 
affinity for its target(s), selectivity profile and 
mode of action. Gathering structural data is an 
essential step in defining the interacting surfaces 
of both the peptide and its target(s). In most 
cases, venom peptides are readily amenable to 
1
H-NMR-based 3-D structure determination. 
Alternatively, computer-assisted molecular 
modeling is an interesting route that can be used 
for peptide structural analysis provided that 
appropriate 3-D structures of related compounds 
are available from databases to serve as 
templates. The accurate structural determination 
of the peptide’s target(s) or, at least, of its binding 
site(s) is a considerably more difficult challenge. 
Although this condition is not always met 
satisfactorily, it is clearly beneficial for the design 
of novel and more potent peptide analogs. 
Structural information, from both peptide and 
target, allow more sophisticated analyses that 
include in silico molecular docking simulations. 
From the most energetically favorable docking 
solutions, relevant hypotheses can be drawn on 
the characteristics of the interacting surfaces 
involved. These can then be verified 
experimentally by using complementary 
mutagenesis of the peptide and its target(s), 
leading to a precise view of the peptide’s 
structural and functional properties.
[4]
 
DESIGN OF NOVEL TOXIN 
ANALOGS BY TARGETED KEY 
RESIDUE REPLACEMENT(S) 
 
This method is largely employed to obtain novel 
analogs with unique pharmacological properties, 
or to pursue detailed structure-function studies. It 
represents the method of choice to address 
whether or not certain amino acid residues from 
the peptide are involved in target recognition and 
binding. It also allows a precise mapping of the 
peptide interacting surface, provided that the 
substituted residues do not alter the global 
peptide conformation.  
 
Generally, residue substitutions are made on a 
systematic basis, using the alanine-scanning 
approach. By this method, the contribution of 
scorpion toxin functional dyads to K
+
 channel 
blockage was experimentally investigated.
[5,6]
 
Mutation of amino acid residues also represents 
a powerful strategy to improve the 
pharmacological value and therapeutic potential 
of a particular peptide. Two general strategies 
can be envisioned. First, substituting amino acid 
residues within the peptide active site. This 
strategy can be used to increase the affinity of 
the peptide towards one specific target, or for 
improving its selectivity profile (similar or 
increased affinity for one target, but decreased 
affinity towards one or several other targets),
[7]
 or 
both.
[8]
  
 
Second, substituting amino acid residues outside 
the peptide active site. This strategy may 
generate more subtle variations in peptide 
pharmacological properties, although in a more 
unpredictable manner. Indeed, it is expected that 
amino acid residue substitutions outside the 
active site should slightly alter the peptide’s 
interacting surface. Stronger conformational 
changes are expected from substitutions that 
target residues key for a proper peptide folding. 
For instance, it has been evidenced that single 
residue mutations in scorpion maurotoxin can 
affect its pattern of disulfide bridging and, hence, 
its conformation and pharmacology.
[9]
  
 
Apart from acting on peptide affinity and 
selectivity by substituting natural amino acid 
residues by others, one can also act on peptide 
stability (e.g. sensitivity to proteases) by using 
non-natural residues for the substitutions instead. 
It is worth mentioning, however, that a similar 
protease resistance can also be acquired by 
selective substitutions based on natural amino 
acid residues only. Owing to the conformational 
change of the peptide that is potentially induced 
by residue substitution, it is wise to gain insight of  
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the structural features of each analog designed, 
produced and tested for bioactivity (e.g. 3-D 
solution structure determination by 
1
H-NMR, 
circular dichroïsm analysis, molecular modeling). 
Combined with docking simulation experiments of 
these analogs over their targets, all the data 
gathered should be of value for a still more 
rational design of novel more potent and/or 
selective peptide analogs by an iterative 
feedback information process. 
 
GAINS IN THE DESIGN OF 
SHORTER PEPTIDES 
 
Since many large peptides (> 50-mer) are not 
readily amenable to chemical production, it may  
appear attractive to reduce their sizes without 
compromising on their pharmacological values. 
Unfortunately, this strategy has seldom been 
used and too little information is available from 
the literature to reasonably conclude on their 
effectiveness. However, some remarks may be 
pertinent. Size reduction of peptides may be used 
for delineation of their pharmacophore(s). 
Similarly, it may prove useful for restricting the 
peptide selectivity profiles. This approach would 
certainly be beneficial in terms of production 
costs and should bypass the complex use of a 
genetic production strategy. In the case of venom 
peptides, one would expect that such a strategy 
should severely decrease the pharmacological 
potencies of the resulting low mass analogs since 
the integrity of the various toxin folds 
characterized so far, that would presumably be 
affected by peptide size reduction, is required for 
the correct spatial distribution of functionally key 
amino acid residues.
[2]
 However, this strategy 
might be particularly valuable for peptides 
presenting small pharmacophores, and thus less 
susceptible to alteration of the active site 
conformation by peptide size trimming. 
 
INTERESTS OF CHIMERA 
MOLECULES AND LABELING 
APPROACHES 
 
Structure-activity relationship studies have 
demonstrated that a given venom peptide can be 
active on several targets (large selectivity profile) 
through different interacting surfaces. The 
existence of a variety of folds in venom 
peptides
[2]
 allows the occurrence of distinct 
relative localizations of the active interacting 
surfaces.
[10]
 For instance, it has been 
documented that scorpion toxins generally fold 
according to the / architectural motif (an N-
terminal helical structure connected by disulfide 
bridges to a C-terminal antiparallel, two- or three- 
 
 
stranded, -sheet structure).
[11]
 Many of these 
scorpion venom peptides act on voltage-gated K
+
 
(Kv) channels through interacting surfaces 
primarily involving their -sheet structures, 
whereas they may interact with small 
conductance Ca
2+
-activated K
+
 (SK) channels 
through opposite interacting surfaces that 
implicate their helical structures. Given the fact 
that interacting surfaces of some venom peptides 
(with enlarged target specificity) are associated 
with residues of specific secondary structures, it 
may be worth using a chimera approach to 
produce peptide analogs with either enlarged or 
restricted pharmacological profiles. A 
representative example of such an approach was 
provided with a chimera made by the N-terminal 
helical region of maurotoxin and the C-terminal - 
sheet region of HsTx1.
[12]
 In this case, a “gain of 
function” was obtained since the chimera 
acquires the activity of maurotoxin on SK 
channels while preserving the pharmacological 
profile of HsTx1 on Kv channels. Conversely, a 
“loss of function” can be attributed to this chimera 
since the activity of maurotoxin on a specific Kv 
channel subtype is lost. The cited approaches 
relate to change in peptide selectivity 
(enlargement or restriction). Of note, the chimera 
approach can tentatively be used to modulate 
peptide affinity towards a particular target without 
altering the initial pharmacological profile. This 
was successfully experienced using a chimera of 
butantoxin and maurotoxin in which the addition 
of the nine N-terminal residues of butantoxin to 
the thirty one C-terminal residues of maurotoxin 
provides some additional molecular contacts for 
the interaction with Kv1.2 channel 
(pharmacophore enlargement), thereby 
enhancing peptide affinity for this channel 
subtype.
[13] 
 
 
Other technical applications are worth 
mentioning. First, peptides can be modified for 
tracking purposes. Tracking can be useful for the 
determination of peptide tissue distribution, sub-
cellular receptor localization or classical binding 
experiments. For example, such an “add-on” 
function has proven valuable for demonstrating 
the cell-penetration ability of maurocalcine, a 
venom peptide acting on intracellular ryanodine-
sensitive Ca
2+
 channels.
[14]
 Site-directed chemical 
modifications of peptides, by labeling with 
fluorescent derivatives or radioactive materials 
(e.g. 
125
I), or biotinylation, are routinely achieved 
for binding experiments. Second, venom peptides 
can be derived to become multifunctional. 
Chemical coupling to other molecules, such as 
antibodies or independent functional domains, 
may represent an interesting strategy for novel 
types of “gain of function”, including cell targeting, 
cell toxicity, cell labeling, cell delivery of 
compounds, etc. Unfortunately, these research 
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avenues are still largely unexploited and their 
add-on values under-evaluated. 
 
STRATEGIES IMPLYING A 
REARRANGEMENT IN DISULFIDE 
BRIDGE PATTERN 
 
Venom peptides are often highly reticulated 
structures.
[2]
 It has been evidenced that disulfide 
bridges contribute to the acquisition and stability 
of the various peptide folds. Secondary structures 
are frequently connected to each other by at least 
one disulfide bridge. The pattern of half-cystine 
connection is also crucial for the correct spatial 
distribution of the functionally key amino acid 
residues from the peptide interacting surfaces. 
Strategies based on the pattern of half-cystine 
pairs can be classified into three categories.  
 
The first one aims at increasing the number of 
disulfide bridges. The extra half-cystine pair 
might decrease peptide flexibility and, possibly, 
that of the interacting surfaces, provided that the 
additional disulfide bridge is inserted in an 
appropriate location within the peptide amino acid 
sequence. In turn, a reduced flexibility may 
lessen peptide adaptability to their target(s) and 
one may expect a greater pharmacological 
selectivity for the analogs designed this way. 
However, an experimental validation of this 
approach is still needed.  
 
In contrast, the second strategy relies on a 
reduction in the number of peptide half-cystine 
pairs instead; a strategy that may conceivably 
increase peptide flexibility thereby potentially 
affecting its pharmacological behavior. In both 
cases, adding or removing a disulfide bridge may 
have consequences on the pattern of other half-
cystine pairs, therefore highlighting the need for a 
careful structural characterization of the analogs.  
 
The third strategy relies on a change in the 
pattern of disulfide bridges within the peptide 
(with or without variation in the number of half-
cystine pairs). Enforcing new disulfide bridge 
arrangements in a peptide is an effective way to 
alter the conformation of its pharmacophore(s) 
and, hence, its pharmacology. This strategy has 
been applied twice for the scorpion maurotoxin. 
By replacing two half-cystine residues belonging 
to two different disulfide bridges, a novel three-
disulfide-bridged maurotoxin analog was 
produced in which the third half-cystine pair was 
unique. This analog still folded along the common 
/ architectural motif of scorpion toxins, while 
presenting a new selectivity towards Kv 
channels.
[15]
 Also, by using an innovative strategy 
of chemical synthesis, a four-disulfide-bridged 
maurotoxin variant was produced in which the  
two last bridges were differently arranged as 
compared to native maurotoxin (although half-
cystine pairings are similar to those found in 
other toxins from the same structural family). 
Again, for this analog, the common architectural 
motif was maintained, but the change in disulfide 
bridge pattern was accompanied by changes in 
pharmacology.
[16]
 
 
It is worth mentioning that removal of all half-
cystine pairs in a reticulated venom peptide - in 
the cases where it has been studied - abolishes 
peptide bioactivity, suggesting that the presence 
of all disulfide bridges are required for the 
maintenance of peptide fold. This property has 
been taken into consideration for peptide-based 
immunizations during vaccination programs, with 
the aim of neutralizing the toxicity of properly 
folded and reticulated toxins.
[17,18]
 
 
ROLE OF DIPOLE MOMENTS IN 
TOXIN-DERIVED PEPTIDES 
 
Many venom peptides exhibit marked electric 
charge anisotropy. A formal representation of this 
anisotropy is given by the peptide dipole moment. 
It has been proposed that the dipole moment 
guides and orients the peptide towards its 
target(s), thereby being key for peptide 
specificity.
[19]
 Although the concept is attractive 
by itself, it remains to be supported 
experimentally. In fact, the main flaw of this 
concept is that it is somehow incompatible with 
the existence of several interacting surfaces, 
which are sometimes located on opposite faces 
of the peptide (e.g. activity of maurotoxin on both 
SK and Kv channels involving opposite faces). 
Noteworthy, the noticeable charge anisotropy of 
venom peptide maurocalcine, which possesses a 
highly basic face, is likely to contribute to its 
singular ability to translocate into cells where the 
peptide acts.
[14]
 This property is shared with other 
cell-penetrating, structurally-unrelated, peptides 
such as Tat and penetratin.
[20]
 
 
FUNCTIONAL DERIVATION OF 
TOXIN-DERIVED PEPTIDES: A 
SEARCH FOR NEW 
APPLICATIONS 
 
Venom peptides exhibit a great variety of folds. In 
the case of animal toxins acting on ion channels, 
up to 14 different types of fold were identified.
[2]
 
Along with other favorable characteristics, such 
as small size and high stability, diversity of fold 
can advantageously be used for a functional 
derivation of venom peptides. Indeed, active sites 
of venom peptides can be substituted by 
functionally unrelated pharmacophores of 
biological value to benefit of the gainful peptide  
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characteristics. For example, the CD4 binding 
surface for the HIV-1 gp120 envelope 
glycoprotein has been successfully transferred 
into the structure of a scorpion toxin possessing 
the / scaffold.
[21]
 This approach leads to the 
production of interesting anti-HIV compounds 
with demonstrated efficacies in vitro. Venom 
peptides with novel pharmacophores represent 
new tools for biological, biotechnological and 
medical applications. A therapeutic development 
may also be envisioned in case the novel 
compounds possess the appropriate drug 
properties. 
 
Other types of functional derivation can be 
achieved that are not necessarily based on the 
replacement of the peptide pharmacophore by an 
exogenous one. In that case, different properties 
of the peptide are derived, such as cell targeting,  
receptor recognition, membrane translocation, 
and nucleic acid binding.  
 
It is worth noting that, in some cases, it is 
mandatory to eliminate the original 
pharmacological activity of the peptide to prevent 
some unwanted side effects. For instance, the 
pharmacological activity of maurocalcine on 
intracellular ryanodine-sensitive calcium channels 
can be suppressed
[22]
 in order to use only its cell-
penetration property for the cell-entry of larger 
non-membrane permeable compounds, including 
whole proteins.
[14]
 In other cases, structures of 
venom peptides can be modified to properly 
target toxins to a given cell type in vivo. Such a 
strategy has been developed in the case of 
immunotoxins, in which a toxin is coupled to a 
cell-targeting ligand or antibody. The main focus 
of the immunotoxin approach is targeted cancer 
therapy.
[23]
 So far, bacterial and plant toxins have 
been used, but the technique could prove 
valuable with animal toxins. 
 
INCREASING PEPTIDE STABILITY 
 
Since the ever-increasing interest in studying 
animal venom peptides is related to their 
potential use in therapeutics, it appears suitable 
to optimize their stability in vivo. Several methods 
can be used to improve peptide stability. Among 
them, one can mention: (i) amino acid residue 
substitution(s) aimed at protecting the peptide 
from proteolytic cleavage. Residue 
replacement(s), which should not alter the 
pharmacophore properties, can be achieved 
using either L-, D-, or non-natural amino acid 
residues (including residues modified on their 
side-chains). (ii) A selective chemical 
modification of the peptide (e.g. changing the 
nature of the N- (acetylation)
[24]
 and/or C-terminal 
extremities (amidation, addition of a specific 
group such as a fatty acid). Such a strategy may  
also be valuable for improving the 
pharmacological characteristics of a given 
peptide, as shown in the case of ShK sea 
anemone toxin in which grafting of a 
phosphotyrosine moiety at the N-terminus 
enhances its selectivity profile towards Kv1.3 
potassium channel.
[25]
 (iii) The replacement of 
natural peptide bonds by pseudo-peptide bonds 
during chemical synthesis (e.g. CO-NH by NH-
CO, or CH2-CH2, or CO-CH2, etc…). (iv) 
Cysteine-based cyclization of the peptide. These 
modifications, which might, by themselves, be 
detrimental to peptide biological properties, 
should be attempted only to overcome specific 
problems, such as short peptide half-life, poor 
peptide stability and/or solubility, and inadequate 
tissue distribution. Of note, although peptide 
modifications have been used in the development 
of several therapeutically useful peptides, it has 
seldom been put into application for venom 
peptides. Apart from chemical modifications of 
the peptides, it is also possible to act on peptide 
stability by using specific delivery systems 
(liposomes, nanoparticles, glycan polymers, 
hydrogels). The latter do not belong to structure-
function strategies and thus will not be developed 
further. 
 
CONCLUSION 
 
Despite the richness in biologically active venom 
peptides, they rarely come by with the desired set 
of characteristics. A rationale structure-function 
strategy is therefore a key step to obtain a 
valuable compound for any given application. 
Strategies are now numerous and have proven to 
be efficient to reach these goals. The choice of a 
particular strategy actually depends on the 
peptide biological properties that one seeks to 
reinforce, create or suppress. Not all strategies 
are equivalent and, sometimes, a combination 
thereof should be used. An iterative feedback 
information process is often required, which 
combines the benefits of several approaches, to 
generate compounds with the appropriate set of 
requisite characteristics. Combined strategies will 
prove valuable for the future development of 
venom peptide-derived drugs in the treatment of 
specific human diseases. 
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